Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2019 1
2020 1
2021 3
2022 1
2023 2
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study.
Puthanakit T, Prompetchara E, Gatechompol S, Ketloy C, Thitithanyanont A, Jongkaewwattana A, Buranapraditkun S, Ubolyam S, Kerr SJ, Sophonphan J, Apornpong T, Kittanamongkolchai W, Siwamogsatham S, Sriplienchan S, Patarakul K, Theerawit T, Promsena P, Nantanee R, Manomaisantiphap S, Chokyakorn S, Hong L, Samija M, Montefiori DC, Gao H, Eaton A, Wijagkanalan W, Alameh MG, Weissman D, Ruxrungtham K; ChulaVac001-Phase 2 study team. Puthanakit T, et al. Sci Rep. 2024 Jan 29;14(1):2373. doi: 10.1038/s41598-023-49653-6. Sci Rep. 2024. PMID: 38287068 Free PMC article. Clinical Trial.
CoronaVac induces lower neutralising activity against variants of concern than natural infection.
Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, Phuphuakrat A, Setthaudom C, Ekronarongchai S, Srichatrapimuk S, Wongsirisin P, Sangrajrang S, Imsuwansri T, Kirdlarp S, Nualkaew S, Sensorn I, Sawaengdee W, Wichukchinda N, Sungkanuparph S, Chantratita W, Kunakorn M, Rojanamatin J, Hongeng S, Thitithanyanont A. Vacharathit V, et al. Among authors: srisaowakarn c. Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26. Lancet Infect Dis. 2021. PMID: 34454652 Free PMC article. No abstract available.
Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study.
Phuphuakrat A, Pasomsub E, Srichatrapimuk S, Kirdlarp S, Suksatu A, Srisaowakarn C, Manopwisedjaroen S, Ludowyke N, Purwono PB, Priengprom T, Wongsa A, Thakkinstian A, Hongeng S, Malathum K, Thitithanyanont A, Tassaneetrithep B. Phuphuakrat A, et al. Among authors: srisaowakarn c. Microbiol Spectr. 2022 Jun 29;10(3):e0050322. doi: 10.1128/spectrum.00503-22. Epub 2022 May 23. Microbiol Spectr. 2022. PMID: 35604133 Free PMC article.
SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile.
Vacharathit V, Srichatrapimuk S, Manopwisedjaroen S, Kirdlarp S, Srisaowakarn C, Setthaudom C, Inrueangsri N, Pisitkun P, Kunakorn M, Hongeng S, Sungkanuparph S, Thitithanyanont A. Vacharathit V, et al. Among authors: srisaowakarn c. Int J Infect Dis. 2021 Nov;112:227-234. doi: 10.1016/j.ijid.2021.09.021. Epub 2021 Sep 15. Int J Infect Dis. 2021. PMID: 34536610 Free PMC article.
Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay.
Polyiam K, Phoolcharoen W, Butkhot N, Srisaowakarn C, Thitithanyanont A, Auewarakul P, Hoonsuwan T, Ruengjitchatchawalya M, Mekvichitsaeng P, Roshorm YM. Polyiam K, et al. Among authors: srisaowakarn c. Sci Rep. 2021 Oct 14;11(1):20383. doi: 10.1038/s41598-021-99642-w. Sci Rep. 2021. PMID: 34650130 Free PMC article.
13 results